Trends in experimental autoimmune prostatitis: insights into pathogenesis, therapeutic strategies, and redefinition
- PMID: 38736617
- PMCID: PMC11087208
- DOI: 10.62347/OUJJ3710
Trends in experimental autoimmune prostatitis: insights into pathogenesis, therapeutic strategies, and redefinition
Abstract
Chronic prostatitis/chronic pelvic pain syndrome (CP/CPSS) is a debilitating condition characterized by prostate inflammation, pain and urinary symptoms. The immune system's response to self-antigens is a contributing factor to CP/CPSS. In this review, we examine the use of experimental autoimmune prostatitis (EAP) in rodents to model salient features of autoimmune mediated CP/CPSS. By exploring etiological factors, immunological mechanisms, and emerging therapeutic strategies, our aim is to enhance our understanding of CP/CPSS pathogenesis and promote the development of strategies to test innovative interventions using the EAP pre-clinical model.
Keywords: AHR; CP/CPPS; ITE; autoimmunity; experimental autoimmune prostatitis; inflammasome; inflammation; therapeutic strategies; translational animal models; urology.
AJCEU Copyright © 2024.
Conflict of interest statement
None.
Figures
Similar articles
-
The aryl hydrocarbon receptor agonist ITE reduces inflammation and urinary dysfunction in a mouse model of autoimmune prostatitis.Am J Clin Exp Urol. 2024 Aug 25;12(4):149-161. doi: 10.62347/PEGK4888. eCollection 2024. Am J Clin Exp Urol. 2024. PMID: 39308590 Free PMC article.
-
Effect of alcohol on chronic pelvic pain and prostatic inflammation in a mouse model of experimental autoimmune prostatitis.Prostate. 2019 Sep;79(12):1439-1449. doi: 10.1002/pros.23866. Epub 2019 Jun 24. Prostate. 2019. PMID: 31233226
-
Experimental autoimmune prostatitis: different antigens induction and antigen-specific therapy.Int Urol Nephrol. 2021 Apr;53(4):607-618. doi: 10.1007/s11255-020-02703-8. Epub 2020 Nov 16. Int Urol Nephrol. 2021. PMID: 33200334 Review.
-
Sodium butyrate alleviates experimental autoimmune prostatitis by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway.Prostate. 2024 May;84(7):666-681. doi: 10.1002/pros.24683. Epub 2024 Mar 5. Prostate. 2024. PMID: 38444115
-
Immunological alterations in patients with chronic prostatitis/chronic pelvic pain syndrome and experimental autoimmune prostatitis model: A systematic review and meta-analysis.Cytokine. 2021 May;141:155440. doi: 10.1016/j.cyto.2021.155440. Epub 2021 Feb 4. Cytokine. 2021. PMID: 33550164
References
-
- Duloy AM, Calhoun EA, Clemens JQ. Economic impact of chronic prostatitis. Curr Urol Rep. 2007;8:336–9. - PubMed
-
- DeWitt-Foy ME, Nickel JC, Shoskes DA. Management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol Focus. 2019;5:2–4. - PubMed
-
- Chen L, Zhang M, Liang C. Chronic prostatitis and pelvic pain syndrome: another autoimmune disease? Arch Immunol Ther Exp (Warsz) 2021;69:24. - PubMed
-
- Liu Y, Mikrani R, Xie D, Wazir J, Shrestha S, Ullah R, Baig MMFA, Ahmed A, Srivastava PK, Thapa KB, Zhou X. Chronic prostatitis/chronic pelvic pain syndrome and prostate cancer: study of immune cells and cytokines. Fundam Clin Pharmacol. 2020;34:160–172. - PubMed
-
- Magistro G, Wagenlehner FM, Grabe M, Weidner W, Stief CG, Nickel JC. Contemporary management of chronic prostatitis/chronic pelvic pain syndrome. Eur Urol. 2016;69:286–97. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous